ERBB2 and breast cancer: Our results show the crucial roles of Shc3 and ErbB2 in modulating P‐gp efficacy in breast cancer cells and suggest that Shc3 inhibition may enhance the sensitivity to chemotherapeutic drugs that target oncogene addiction pathways.